41 peer-reviewed studies · Evidence score: 9/10
Borges-Vieira JG et al. • Nutritional neuroscience (2023)
As for anxiety symptoms, the availability of results is limited to adjuvant vitamin D therapy.
Maruf AA et al. • Pharmacopsychiatry (2022)
Adjunctive L-methylfolate may have modest efficacy in antidepressant-treated adults with MDD.
Sakuma K et al. • Psychopharmacology (2018)
Our findings suggest that pooled FA + AP treatment improves negative symptoms in schizophrenia patients.
Andras A et al. • The Cochrane database of systematic reviews (2013)
Currently, no recommendation can be made regarding the value of treatment of hyperhomocysteinaemia in peripheral arterial disease.
Sarris J et al. • The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry (2022)
Based on the current data and clinician input, a range of nutraceuticals and phytoceuticals were given either a supportive recommendation or a provisional recommendation across a range of various psychiatric disorders.
Lam NSK et al. • Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2022)
Increasing evidence from clinical trials consistently demonstrate folate supplements, especially levomefolic acid or 5-methylfolate, may improve clinical outcomes for certain psychiatric diseases, especially as an adjunct pharmacotherapy with minimal side effects.
Altaf R et al. • Complementary therapies in medicine (2021)
Adjunct therapy with l-Methylfolate or folic acid improves depression scale scores, patient response, and remission rates.
Bayes J et al. • Journal of alternative and complementary medicine (New York, N.Y.) (2019)
This review has found a number of methodological limitations and conflicting results.
Roberts E et al. • Journal of psychopharmacology (Oxford, England) (2018)
All evidence was graded as low or very low quality for each outcome.
Batllori M et al. • Journal of inherited metabolic disease (2018)
High CSF HVA values, together with a severe cerebral folate deficiency, were observed in KSS patients and in other mtDNA mutation syndromes.
Sarris J et al. • The American journal of psychiatry (2016)
Current evidence supports adjunctive use of SAMe, methylfolate, omega-3, and vitamin D with antidepressants to reduce depressive symptoms.
Liew SC, Gupta ED • BioMed Research International (2015)
MTHFR variants affect 30-40% of the population and impair folate metabolism.
Perva IT et al. • Medicina (Kaunas, Lithuania) (2024)
These findings suggest that this supplementation regimen could be a beneficial adjunct therapy for improving liver health in adults with obesity-induced MASLD.
Coppen A, Bolander-Gouaille C • Journal of Psychopharmacology (2005)
Low folate status is linked to poor antidepressant response and depression severity.
Chaban ОS et al. • Wiadomosci lekarskie (Warsaw, Poland : 1960) (2023)
Conclusions: The received results confirm the available evidence for the properties of SAMe in depression and complement them with evidence of the ef-fectiveness of the Deprilium® complex that contains SAMe and L-methylfolate with methylcobalamin, which together produce pharmacological and clinical synergy to reduce the severity of subclinical depressive manifestations in patients with NCD.
Pokushalov E et al. • Nutrients (2024)
Methylfolate, P5P, and methylcobalamin supplementation tailored to genetic profiles effectively reduced homocysteine and LDL-C levels in patients with specific MTHFR, MTR, and MTRR polymorphisms, particularly with homozygous minor allele polymorphisms.
Siddique A et al. • BMC pharmacology & toxicology (2025)
Combination therapy of antidepressants with low-dose methylfolate may provide a safe and effective treatment strategy for patients with depressive disorder.
Mischoulon D et al. • The Journal of clinical psychiatry (2012)
Despite concerns about the impact that SAMe therapy may have on homocysteine levels and risk of adverse cardiovascular effects, the lack of significant increase in tHCY levels after treatment suggests that no toxic effects from SAMe should be expected.
Obeid R et al. • The American journal of clinical nutrition (2023)
Folate intake from infant formula according to the present EU legislation increased RBC folate and plasma pABG concentrations in infants to a greater extent than breastfeeding, particularly in carriers of the TT genotype.
Ambrosino P et al. • Nutrition research (New York, N.Y.) (2015)
In the 246 enrolled subjects, a significant reduction of tHcy levels occurred after the first cycle of treatment (from 31.6 ± 13.6 to 14.4 ± 5.77 μmol/L, P < .001) and during the whole 2-year follo...